Wockhardt gets USFDA nod for anti-fungal drug

New Delhi, May 31 (UNI) Pharma company Wockhardt today said it has received US Food and Drug Administration (USFDA) approval to market Terbinafine tablets (Lamisil), an anti-fungal drug in the US.

''The US market for Terbinafine tablets is about 680 million dollars. Tapping this market, in addition to increasing product portfolio' is a manifestation of our rapidly expanding capabilities in the US,'' company's Chairman and Managing Director Habil Khorakiwala said.

The Terbinafine tablets are manufactured at the company's USFDA certified formulation plant at Waluj, Maharashtra.

The company currently markets 20 products in the US market.

UNI